NASDAQ:IRD Opus Genetics 3/31/2025 Earnings Report $1.80 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.81 +0.01 (+0.50%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Opus Genetics EPS ResultsActual EPS-$1.27Consensus EPS -$0.34Beat/MissMissed by -$0.93One Year Ago EPSN/AOpus Genetics Revenue ResultsActual Revenue$3.40 millionExpected Revenue$11.10 millionBeat/MissMissed by -$7.70 millionYoY Revenue GrowthN/AOpus Genetics Announcement DetailsQuarterDate3/31/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsOpus Genetics' next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Opus Genetics Earnings HeadlinesOpus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025October 2 at 8:00 AM | globenewswire.comOpus Genetics, Inc. - Special CallSeptember 30 at 1:01 PM | seekingalpha.comArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.October 2 at 2:00 AM | Banyan Hill Publishing (Ad)Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)September 30 at 7:00 AM | globenewswire.comInstitutions profited after Opus Genetics, Inc.'s (NASDAQ:IRD) market cap rose US$15m last week but private equity firms profited the mostSeptember 26, 2025 | finance.yahoo.comInstitutions profited after Opus Genetics, Inc.'s (NASDAQ:IRD) market cap rose US$15m last week but private equity firms profited the mostSeptember 26, 2025 | finance.yahoo.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
